Danaher Corp.

Fourth Quarter Performance: Danaher Corporation reported Q4 2024 sales of $6.5 billion, achieving 1% core revenue growth. The full-year sales totaled $23.9 billion, seeing a 1.5% decline in core revenue year-over-year. Adjusted operating profit margin improved to 29.6%, a 90 basis point increase, while adjusted diluted net earnings per share rose by 2.4% to $2.14.

2025 Guidance and Forecasts: For FY 2025, Danaher anticipates core revenue growth of approximately 3%, with expected Q1 core revenue to decline in the low-single-digit percentage range. Notable cost headwinds include an estimated 2% negative impact from the strengthening U.S. dollar, alongside expected declines in specific segments, particularly Pall and Genomics.

Life Sciences Segment Challenges: The Life Sciences division faces noise due to government funding in the U.S. and cautious capital spending in China. Overall, it’s projected to have low-single-digit growth, with expectations for improvement as the year progresses. This cautious outlook reflects longer recovery times than initially expected.